Printer Friendly

Sentigen Congratulates Nobel Prize Winner.

PHILLIPSBURG, N.J. -- Joseph K. Pagano, the Chairman of the Board of Sentigen Holding Corp. ("Sentigen") (NasdaqSC:SGHL), a biotechnology company which has entered the field of drug discovery utilizing its proprietary Tango(TM) Assay System and is exploring entry into the fields of insect olfaction for crop protection and insect vectors involved in human diseases, extends congratulations to Dr. Richard Axel, Sentigen's long term good friend and consultant, on being co-awarded the Nobel Prize for Medicine for his pioneering work on the olfactory system.

Mr. Pagano stated that the study of olfactory receptors referred to in the Nobel Prize citation is a focus of Sentigen's research and development activities. Sentigen has filed patent applications with respect to its work in this field.

Sentigen previously announced on August 3, 2004 that it had been awarded a federal contract by the Technical Support Working Group, an interagency government office with representatives from the Departments of Defense, State and Homeland Security, to develop advanced biotechnology for the detection of explosives and other threats. The contract, entitled "Olfactory Receptor Microarray-Based Sensor for Explosives Detection (ORM-EDS)", will provide Sentigen with $1.65 million in research funding over the next 2 years.

Sentigen is a holding company conducting business through two wholly-owned operating subsidiaries, Cell & Molecular Technologies, Inc. ("CMT"), and Sentigen Biosciences, Inc. CMT provides contract research and development services and manufactures specialty cell culture media, reagents and other research products for companies engaged in the drug discovery process. Sentigen Biosciences is primarily engaged in the development and commercialization of novel bioassay systems that elucidate the underlying biology of protein-protein interactions, including those involving olfactory receptors. Sentigen Biosciences is initially targeting its Tango(TM) Assay System to address the functionalization of G protein-coupled receptors (GPCRs) for pharmaceutical drug discovery and development. Sentigen Biosciences has filed patent applications on its Assay System and expects to file additional patent applications on this technology in the future.

For further information about Sentigen, we refer you to our various filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Forward-Looking Statements

The statements contained herein which are not historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect Sentigen's actual results, performance, or achievements in the future and, accordingly, such actual results, performance, or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on behalf of Sentigen. These risks and uncertainties include, but are not limited to, those risks described in Sentigen's Form 10-K for the year ended December 31, 2003. Actual results may vary significantly from such forward-looking statements. The words "believe," "expect," "anticipate," "intend," and "plan" and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date the statement was made.

Excerpts from the citation awarding the 2004 Nobel Prize in physiology or medicine to Americans Richard Axel and Linda B. Buck for their discoveries in the biology of the sense of smell:

The sense of smell has long remained the most enigmatic of our senses. The basic principles for recognizing and remembering about 10,000 different odors were not understood. This year's Nobel Laureates in physiology or medicine have solved this problem and in a series of pioneering studies clarified how our olfactory system works. They discovered a large gene family, comprised of some 1,000 different genes (3 percent of our genes) that give rise to an equivalent number of olfactory receptor types. These receptors are located on the olfactory receptor cells, which occupy a small area in the upper part of the nasal epithelium and detect the inhaled odorant molecules.

The conclusion that each olfactory receptor cell only expresses one single odorant receptor gene was highly unexpected. Axel and Buck continued by determining the organization of the first relay station in the brain. The olfactory receptor cell sends its nerve processes to the olfactory bulb, where there are some 2,000 well-defined micro regions, glomeruli. There are thus about twice as many glomeruli as the types of olfactory receptor cells.

The general principles that Axel and Buck discovered for the olfactory system appear to apply also to other sensory systems. Pheromones are molecules that can influence different social behaviors, especially in animals. Axel and Buck, independent of each other, discovered that pheromones are detected by two other families of GPCR, localized to a different part of the nasal epithelium. The taste buds of the tongue have yet another family of GPCR, which is associated with the sense of taste.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 5, 2004
Previous Article:Johnson Capital Arranges Over $500 Million in 30 Days.
Next Article:One Down -- 3,599,999 Units to Go; New Zealander Becomes First Customer Under Nissan's One Million Additional Sales Plan.

Related Articles
Nobel prizes mark 100th anniversary.
Transhumanism and the future.
Nobel celebrations: an elegant turn with science's elite.
Project begins to create monument to peacemakers.
1000 Peacewomen miss out on Nobel Peace Prize.
Father-son event.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters